

DATE: May 16, 2005

SHEET 1 of 3

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

5973.US.D3

10/816,326

APPLICANT

J. Henslee & P. N. Friedman

FILING DATE

GROUP

April 1, 2004

1645 1643

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
amb	A1	5,668,267	09/16/1997	Watson, et al.	—	—	
	A2	4,816,567	03/28/1989	Cabilly, et al.	—	—	
	A3	4,946,778	08/07/1990	Ladner, et al.	—	—	
	A4	5,254,458	10/19/1993	Mimms	—	—	
	A5	2002/0009738	01-2002	Houghton, et al.	—	—	
	A6	6,379,671	04/30/2002	Colpitts	—	—	
	A7	2003/0059432	03/2003	Dillon and Fanger	—	—	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
							YES	NO
amb	B1	97/34997	25 Sep 97	PCT	—	—		
	B2	2276169	21 Sep 94	GB	—	—		
	B3	84/03564	13 Sep 84	EPO	—	—		
	B4	0473065	04 Mar 92	EPO	—	—		
	B5	0326100	11 Sep 96	EPO	—	—		
	B6	0406473	20 Sep 95	EPO	—	—		
	B7	0273115	07 Sep 94	EPO	—	—		
	B8	0425633	27 Jul 94	EPO	—	—		
	B9	0424634	14 Jun 95	EPO	—	—		
	B10	95/20681	03 Aug 95	PCT	—	—		
	B11	92/01936	06 Feb 92	PCT	—	—		
	B12	98/21331	05-1998	WO	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

amb	C1	G.N. Hortobagyi, et al., <u>CA Cancer J Clin</u> 45:199-226 (1995)
	C2	J.R. Harris, et al. <u>Cancer: Principles and Practice of Oncology</u> , Fourth Edition, 1264-1332, Philadelphia, PA: J/B. Lippincott Co. (1993)
	C3	C.J. Wright, et al., <u>Lancet</u> 346:29-32 (1995)
	C4	M.K. Schwartz, <u>Cancer: Principles and Practice of Oncology</u> , Vo.1, Fourth Edition, pp. 531-542, Philadelphia, PA: J/B Lippincott Co. (1993)
	C5	K. Pantel, et al., <u>Onkologie</u> 18:394-401 (1995)
	C6	G.E. Hanks, et al, <u>Cancer: Principles and Practice of Oncology</u> , Vol. 1, Fourth Edition, pp. 1073-1113, Philadelphia, PA: JB Lippincott Co. (1993)
	C7	E.R. Frykberg, et al., <u>Cancer</u> 74:350-361 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

DATE: May 16, 2005

SHEET 2 of 3

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 5973.US.D3	SERIAL NO. 10/816,326
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT J. Henslee & P. N. Friedman	
(Use several sheets if necessary)	FILING DATE April 1, 2004	GROUP 1645 1643

(37 CFR 1.98 (b))

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

amh	C8	T.E. Creighton, et al. <u>Proteins: Structures and Molecular properties, Second Edition</u> , pp. 78-102, New York, NY:WH Freeman and Co. (1993)
	C9	L. Miele, et al., <u>J. Endocrinol. Invest.</u> 17:679-692 (1992)
	C10	R.Bally, et al., <u>J. Mol Biology</u> 206:153-170 (1989)
	C11	I. Morize, et al., <u>J. Mol Biol</u> , 194:725-739 (1987)
	C12	T.C. Umland, et al., <u>Nature Structural Biology</u> , 1:538-545 (1994)
	C13	Grunewald, K., et al., <u>Lab. Invest.</u> , Mammaglobin Gene Expression: A Superior Marker fo Brast Cancer Cells in Peripheral Blood in Comparison to Epidermal-Growth-Factor Receptro and Cytokeratin-19, 80: 1071-1077, (2000)
	C14	T.C. Umland, et al., <u>J. Mol. Biol.</u> 224:441-448 (1992)
	C15	O.A. Duffort, et al., <u>Molecular Immunology</u> 28:301-309 (1991)
	C16	K. Leitermann, et al., <u>J. Of Allergy and Clinical Immunology</u> , 74:147-153 (1991)
	C17	M. Parker et al., <u>Nature</u> , 298:92-94 (1982)
	C18	J.P. Morgenstern, et al., <u>PNAS</u> , 88:9690-9694 (1991)
	C19	M.A. Watson, et al., <u>Cancer Research</u> , 56:860-865 (1996)
	C20	M.A. Watson, et al., <u>Oncogene</u> , 16: 817-824 (1998)
	C21	O. Zach, et al., <u>Detection of Circulating Mammary Carcinoma Cells in the Peripheral Blood of Breast Cancer Patients Via a Nested Reverse Transcriptase Polymerase Chain Reaction Assay for Mammaglobin mRNA J. Clin. Oncol</u> , 17:2015-2019 (1999)
	C22	H.J. Kahn, et al., <u>RT-PCR amplification of CK19 mRNA in the Blood of Breast Cancer Patients: Correlation with Established Prognostic Parameters Breast Cancer Res. Treat</u> , 60: 143-151 (2000)
	C23	Isao Miysahiro, et al., <u>Molecular Strategy for Detecting Metastatic Cancers with Use of Multiple Tumor-specific MAGE-A Genes, Clinical Chemistry</u> , 47: 3 505-512 (2001)
	C24	Smith & Waterman, <u>Advances in Applied Mathematics</u> 2:482-442 (1981)
	C25	Dayhoff, <u>Atlas of Protein Sequences and Structure</u> , M.O. Dayhoff, ed. 5 Suppl. 3:353-358
	C26	Gribskov, <u>Nucl. Acids Res.</u> , 14(6): 6745-6763 (1986)
	C27	F. Wold, <u>Posttraslational Protein Modifications: Perspectives and Prospects</u> , pp. 1-12, B.C. Johnson, Ed., Academic Press, New York (1983)
	C28	Seifter, et al., <u>Analysis for Protein Modification and Non Protein Cofactors</u> , <u>Meth. Enzymol.</u> , 182: 626-464 (1990)

EXAMINER amh	DATE CONSIDERED 22 March 2007
-----------------	----------------------------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

DATE: May 16, 2005

SHEET 3 of 3

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

5973.US.D3

SERIAL NO.

10/816,326

APPLICANT

J. Henslee & P. N. Friedman

FILING DATE

April 1, 2004

GROUP

1645 1643

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

amh	C29	Rattan, et al., <u>Protein Synthesis: Posttranslational Modifications and Aging</u> , Ann N.Y. Acad Sci., 663: 48-62 (1992)
	C30	Inbar, et al., <u>Proc. Natl. Acad. Sci. USA</u> , 69: 2659-2662 (1972)
	C31	Winter, et al., <u>Nature</u> , 349: 293-299 (1991)
	C32	Ehrlich, et al., <u>Biochem</u> , 19: 4091-4096 (1980)
	C33	Huston, et al., <u>Proc. Natl. Acad. Sci. USA</u> 85: 5879-5883 (1988)
	C34	Riechmann, et al., <u>Nature</u> , 332: 323-327 (1988)
	C35	Verhoeyan, et al., <u>Science</u> 239: 1534-1536 (1988)
	C36	J. Hodgson, <u>Bio/Technology</u> 9:19-21 (1991)
	C37	S. Braxton, et al., <u>Biochemistry</u> , 31:7796-7801 (1992)
	C38	S.B.P. Athauda, et al., <u>J. Biochem (Tokyo)</u> 113 (6):742-746 (1993)
	C39	Gluzman, <u>Cell</u> , 23:175 (1981)
	C40	Price, et al., <u>J. Biol. Chem</u> 244:917 (1969)
	C41	Kohler and Milstein, <u>Nature</u> 256:495-497 (1975)
	C42	Kozbor, et al., <u>Immun. Today</u> , 4:72 (1983)
	C43	Cole, et al., <u>Monoclonal Antibodies and Cancer Therapy</u> , Alan r. Liss, Inc., New York, NY pp. 77-96 (1985)
	C44	Sumerdon, et al., <u>Nucl. Med. Biol</u> , 17:247-254 (1990)
	C45	Griffin, et al., <u>J. Clin Onc</u> , 9:631-640 (1991)
	C46	R.B. Lauffer, <u>Magnetic Resonance in Medicine</u> , 22:339-342 (1991)
	C47	Garnett and Baldwin, <u>Cancer Research</u> 46:2407-2412 (1986)
	C48	Pastan, et al., <u>Cell</u> 47:641-648 (1986)
	C49	Goodwin and Meares, <u>Cancer Supplement</u> , 80:2675-2680 (1977)
	C50	Mimms, et al., <u>Virology</u> 176:604-619 (1990)
	C51	V. Van Heyningen <u>Methods in Enzymology</u> , Vol. 121, p. 472 (1986)
	C52	X. Qiu, et al., <u>Journal of Immunology</u> , Vol. 156, p. 3350 (1996)
	C53	F.L. Graham, et al., <u>J. Gen. Vir.</u> , 36:59-72 (1977)
amh	C54	S.R. Kain, et al., <u>Biotechniques</u> , 17:982 (1994)

EXAMINER

amh

DATE CONSIDERED

22 March 2007

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)